Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Shares Bought by Barclays PLC
Barclays PLC significantly increased its stake in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) by 10,601,800.0% during Q4, owning 106,019 shares valued at $567,000. Other institutional investors also adjusted their positions, with hedge funds owning 46.64% of the company. Corvus Pharmaceuticals shares rose 4.7% to $3.35, with a market cap of $228.37 million. Analysts have a consensus rating of "Moderate Buy" with an average price target of $15.67. The company focuses on developing immune modulator products for various diseases, including solid cancers.
Barclays PLC raised its holdings in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) by 10,601,800.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 106,019 shares of the company's stock after purchasing an additional 106,018 shares during the period. Barclays PLC owned 0.16% of Corvus Pharmaceuticals worth $567,000 at the end of the most recent quarter.
Get Corvus Pharmaceuticals alerts:
Several other hedge funds and other institutional investors have also recently made changes to their positions in CRVS. Jane Street Group LLC acquired a new position in Corvus Pharmaceuticals during the 3rd quarter valued at about $265,000. Virtu Financial LLC purchased a new stake in shares of Corvus Pharmaceuticals during the third quarter worth about $83,000. JPMorgan Chase & Co. increased its holdings in shares of Corvus Pharmaceuticals by 441.5% during the third quarter. JPMorgan Chase & Co. now owns 49,556 shares of the company's stock valued at $262,000 after acquiring an additional 40,404 shares in the last quarter. Avity Investment Management Inc. increased its holdings in shares of Corvus Pharmaceuticals by 7.6% during the fourth quarter. Avity Investment Management Inc. now owns 29,680 shares of the company's stock valued at $159,000 after acquiring an additional 2,100 shares in the last quarter. Finally, Masso Torrence Wealth Management Inc. raised its position in shares of Corvus Pharmaceuticals by 200.0% in the 4th quarter. Masso Torrence Wealth Management Inc. now owns 30,000 shares of the company's stock valued at $160,000 after purchasing an additional 20,000 shares during the last quarter. Hedge funds and other institutional investors own 46.64% of the company's stock.
Corvus Pharmaceuticals Trading Up 4.7 %
Shares of NASDAQ CRVS opened at $3.35 on Friday. The company has a 50 day simple moving average of $3.61 and a two-hundred day simple moving average of $5.51. The stock has a market cap of $228.37 million, a price-to-earnings ratio of -3.60 and a beta of 0.67. Corvus Pharmaceuticals, Inc. has a 12 month low of $1.75 and a 12 month high of $10.00.
Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01). Analysts forecast that Corvus Pharmaceuticals, Inc. will post -0.63 EPS for the current year.
Wall Street Analyst Weigh In
A number of brokerages have issued reports on CRVS. Oppenheimer restated an "outperform" rating and set a $15.00 price target (up previously from $14.00) on shares of Corvus Pharmaceuticals in a research note on Wednesday, March 26th. HC Wainwright reissued a "buy" rating and issued a $11.00 target price on shares of Corvus Pharmaceuticals in a research report on Wednesday, March 26th. One investment analyst has rated the stock with a sell rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $15.67.
Read Our Latest Report on Corvus Pharmaceuticals
Corvus Pharmaceuticals Profile
(Free Report)Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.
Featured Stories
- Five stocks we like better than Corvus Pharmaceuticals
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- IBM's AI Offensive: Assessing IBM's Path to Renewed Growth
- Upcoming IPO Stock Lockup Period, Explained
- Rockwell Automation: Tailwinds From Onshoring U.S. Production
- Compound Interest and Why It Matters When Investing
- Is Energy Transfer Undervalued or a Value Trap?
Want to see what other hedge funds are holding CRVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Corvus Pharmaceuticals Right Now?
Before you consider Corvus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Corvus Pharmaceuticals wasn't on the list.
While Corvus Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
